Concepedia

Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer

Brian I. Rini, Nicholas J. Vogelzang, M Dumas, James L. Wade, David Taber, Walter M. Stadler

Journal of Clinical Oncology · 2000 · 155 citations · 14 references

DOI

Abstract

Weekly gemcitabine with continuous infusion 5-FU is an active combination in patients with metastatic RCC. Therapy was well tolerated and produced an improvement in progression-free survival over historical controls.

References

14

Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2

Steven A. Rosenberg · JAMA · 1994 · 1.1K citations

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

James L. Abbruzzese, Ralf Grunewald, Elizabeth A. Weeks et al. · Journal of Clinical Oncology · 1991 · 757 citations

, , +12

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

Volker Heinemann, Yi-Zheng Xu, Sherri Chubb et al. · Molecular Pharmacology · 1990 · 405 citations

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

A Yagoda, B Abi-Rached, Daniel P. Petrylak · PubMed · 1995 · 388 citations

, , +5

2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase

C. H. Baker, Jennifer A. Banzon, J. Martin Bollinger et al. · Journal of Medicinal Chemistry · 1991 · 252 citations · Full text